2 / 10
allied
academies
CANCER THERAPY AND ONCOLOGY
NEUROLOGY AND BRAIN DISORDERS
&
International Conference on
International Conference on
J u n e 2 1 - 2 2 , 2 0 1 8 | O s a k a , J a p a n
Allied Journal of Medical Research
|
Volume 2
Page 14
Joint Event on
O
ne of the most significant problems of cancer therapy is the
damaging activity of anticancer drugs against normal body cells.
All attempts to develop a therapeutic agent with a selective cytotoxic
effect on tumor cells had no much success because of the high
degree of biological identity between healthy and malignant cells.
The celandine is being used in the medicine over more than 3500
years. The first data concerning the therapeutic effect of the juice of
cel-andine in the patient with malignant melanoma were published in
Germany in 1536. From that time drugs based on biologically active
substances of celandine are widely used to treat cancer and non-cancer
disease. It is well known that tumor cell is more negatively charged as
compared to normal cell. We have used this feature of the tumor cell
to give NSC631570 a property to selectively interact with it, without
endangering healthy cells and tissues. The drug is strongly positively
charged. Due to this it has an ability to be selectively accumulated in
tumor tissue and to induce tumor cell apoptosis only in tumor cells
without harmful effect on normal cells. Potent selective antitumor
effect of NSC631570 repeatedly proven by the results of clinical trials.
Until now this preparation has been tested on over 100 cancer cell lines
and on 12 normal cell lines and the results of the studies carried out in
more than 120 universities and research centers (in particular at the
National Cancer Institute (the USA)) have shown that the NSC 631570
killed only cancer cells without having damaged the nor-mal cells what
confirmed its selective effect.
Biography
Wassil Nowicky is the Director of “Nowicky Phar-
ma” and President of the Ukrainian Anti-Cancer
Institute (Vienna, Austria). He has finished his
study at the Radiotechnical Faculty of the Tech-
nical University of Lviv (Ukraine) with the end of
1955 with graduation to “Diplomingeniueur” in
1960 which title was nostrificated in Austria in
1975. He became the very first scientist in the
development of the anticancer protonic therapy
and is the inventor of the preparation against can-
cer with a selective effect on basis of celandine
alkaloids “NSC-631570”. He used the factor that
cancer cells are more negative charged than nor-
mal cells and invented the Celandine alkaloid with
a positive charge thanks to which it accumulates
in cancer cells very fast. Thus, He is invited as an
Honorable Speaker to take part in many sci-en-
tific international congresses and conferences
in USA, Australia, Japan, UAE, Europe. Author of
over 300 scientific articles dedicated to cancer
research. He is a real member of the New York
Academy of Sciences, member of the European
Union for applied immunology and of the Ameri-
can Association for scientific progress, honorary
doctor of the Janka Kupala University in Hrodno,
doctor “honoris causa” of the Open international
university on complex medicine in Colombo, hon-
orary member of the Austrian Society of a name
od Albert Schweizer. He has received the award
for merits of National guild of pharmasists of
America. the award of Austrian Society of sani-
tary, hygiene and public health services and oth-
ers.
dr.nowicky@yahoo.deSELECTIVE AND
IMMUNOMODULATING
PROPERTIES OF THE ANTICANCER
PROTON PREPARATION ON
BASIS OF GREATER CELANDINE
ALKALOIDS NSC631570
Wassil Nowicky
Nowicky Pharma
Wassil Nowicky, Allied J Med Res 2018, Volume 2